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SUMMARY – One of the main reasons for the introduction of a new grading system was Gleason 
sum 7, which diff ered signifi cantly in the prognosis of the disease depending on the primary Gleason. 
Th e aim of this study was to compare grade group 2 and grade group 3, and the impact of cancer 
percentages in fi nal pathology reports after radical prostatectomy on the occurrence of T3 stage of the 
disease after radical prostatectomy of clinically localized prostate cancer. Th e study covered 365 pa-
tients with clinically localized prostate cancer who underwent radical retropubic prostatectomy (RRP) 
over the period of two years. Th e average percentage of carcinomas found in pathology reports after 
RRP was 20.1%. With the increase in the grade group, the average percentage of carcinomas in pa-
thology reports increased signifi cantly, p<0.001. With regard to grade groups 2 and 3, irrespective of 
cancer percentages in pathology reports, more cases of T3 stage were found in grade group 3 when 
compared to grade group 2, which was statistically signifi cant (p<0.001). However, grade group 2 and 
grade group 3 patients with ≤10% cancer occurrences in fi nal pathology reports after RRP did not 
show any statistical signifi cance in the occurrence of T3 stage, p=0.96. Prognostic diff erences in grade 
group 2 and grade group 3 patients after RRP are signifi cant, but not in all cases, because of their 
dependence on the percentage of cancer in the fi nal pathology report after RRP of clinically localized 
prostate cancer.
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Introduction
Th e Gleason score (GS) is the most commonly ac-
cepted and widely used parameter for the prediction of 
tumor biology and treatment outcomes. Th e Gleason 
grading system is the best independent predictor for 
prostate cancer progression after radical prostatecto-
my. Since its introduction1, the Gleason grading sys-
tem has undergone several revisions in order to im-
prove reproducibility and prognostic value2,3,4. Most 
recently, a new grading system has been proposed by 
the International Society of Urological Pathology 
(ISUP) and has been integrated into the 2016 WHO 
Classifi cation of Tumors of the Urinary System and 
Male Genital Organs5.
Th e new grading system, ranging from 1 to 5, pro-
vides a simplifi ed classifi cation system for predicting 
the risk of disease progression after radical prostatec-
tomy. One of the main reasons for the introduction of 
the new grading system was Gleason sum 7, which 
diff ered signifi cantly in the prognosis of the disease 
depending on the primary Gleason5, 6, 7.
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Th e aim of the study was to compare grade group 2 
(GS 3+4) with grade group 3 (GS 4+3) and the impact 
of canc er percentage in fi nal pathology reports on the 
occurrence of T3 stage after radical prostatectomy in 
clinically localized prostate cancer.
Patients and methods
Th e study involved patients hospitalized in the De-
partment of Urology at Sestre milosrdnice University 
Hospital Center who underwent RRP in the period 
between January 2015 and the end of 2016. We ana-
lyzed all patients who had undergone RRP using hos-
pital records, operative protocols and pathology re-
ports.
Th is retrospective study included 365 patients out 
the total of 371 patients. One patient was excluded be-
cause of lacking pathology reports and 5 other patients 
due to missing PSA levels. All patients in the study 
had clinically localized prostate cancer and underwent 
RRP. Th e average age of patients who had undergone 
surgery was 64.67 years. Th e youngest patient was 47 
and the oldest 78 (Table 1). Th ere was a large number 
of patients in the range of 66-70 years of age in our 
cohort (n=123, 33.79%). We also had a signifi cant 
number of patients over the age of 70 (n=60, 16.48%). 
Th e lowest number of patients in the cohort was 
younger than 55, only 6.59%. PSA levels ranged from 
1.70 ng/ml to 88.92 ng/ml, with the mean PSA value 
of 11.61 and median value of 8.51 ng/ml (Table 1). 
Th e minimum PSA level was 1.7 ng/ml and was found 
in grade group 2, while the highest PSA level was 88.9 
ng/ml and was found in grade group 3. Th e highest 
median level of PSA, measuring 15.1 ng/ml, was, ex-
pectedly, found in grade group 5. Th e most common 
grade groups were grade group 2 with 50.41%, and 
grade group 3, with a share of 36.16%, while grade 
group 1 was represented by only 4.38% of the included 
patients (Fig. 1). We also had only 10 grade group 5 
patients (2.74%). Th e average percentage of carcino-
mas found in pathology reports following RRP was 
20.1%, ranging from 5 to 80% (Fig. 2). Th e minimum 
Table 1. Age and PSA patient characteristic
N Mean SD Minimum Maximum Percentiles25th 50th (Median) 75th
Age (years) 365 64.67 6.14 47.00 78.00 60.00 66.00 69.00
PSA level 365 11.61 10.36 1.70 88.92 6.37 8.51 12.75
Fig. 1. Grade groups characteristic: Th e most common 
grade group was grade group 2 with 50.41% and grade 
group 3 with a share of 36.16%, while grade group 1 was 
represented by only 4.38% of the included patients.
Fig. 2. Relationship between grade groups and cancer 
percentage: With the increase in the grade group, the 
average percentage of carcinomas in pathology report 
found after RRP also increased, p <0.001.
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of 5% was found in grade group 1, while the largest 
percentage of 80% was found in grade group 4. Out of 
the total number of 365 patients operated on within 
the selected period, T2 stage was found in 247, and T3 
stage in 118 patients. In grade group 2, there were 153 
patients with T2 stage of the disease and 31 patients 
with T3 stage in the fi nal pathology report. In grade 
group 3, there were 72 patients with T2 stage and 60 
patients with T3 stage in the fi nal pathology report. 
When we observed patients with ≤10% of carcinoma 
in the fi nal pathology report, there were 68 patients 
with T2 stage in grade group 2 and 12 patients with 
T3 stage of the disease. In grade group 3, there were 50 
patients with T2 stage and 9 patients with T3 stage.
Statistics
Th e Kolmogorov–Smirnov tests were used to test 
the hypothesis of normal distribution. Normally dis-
tributed continuous data were reported as mean (stan-
dard deviation, SD), while interval data and ordinal 
data without normal distribution were reported as me-
dian (interquartile range) and evaluated using the 
Kruskal-Wallis test. Categorical variables were pre-
sented as count (percentages) and were evaluated us-
ing chi-square and Fisher tests where appropriate. 
Spearmans correlation coeffi  cients were calculated to 
assess the correlation between PSA levels and tumor 
clinical characteristics. All P levels <0.05 were consid-
ered signifi cant. All statistical procedures were per-
formed using IBM SPSS Statistics version 24.
Results
Th e average age of patients who had undergone 
surgery was 64.67 years. Th e youngest patient was 47 
and the oldest 78 years old (Table 1). Patient age did 
not increase with the increase of the grade group, 
p=0.48. PSA levels ranged from 1.70 ng/ml to 88.92 
ng/ml, with the mean PSA value of 11.61, and the me-
dian value of 8.51 ng/ml (Table 1). PSA levels in-
creased signifi cantly with the increase of the grade 
group, p<0.001. Th e most common grade groups were 
grade group 2, with 50.41%, and grade group 3, with a 
share of 36.16%, while grade group 1 was represented 
by only 4.38% of the included patients (Fig. 1). Th e 
average percentage of carcinoma found in pathology 
reports after RRP was 20.1%, ra nging from 5 to 80%. 
Th e average percentage of carcinoma in pathology re-
ports found after RRP also increased with the increase 
in the grade group, p<0.001 (Fig. 2). Furthermore, the 
increase in tumor percentage per group was accompa-
nied by an increase in PSA values, p<0.001 (Fig. 3). 
Out of the total number of 365 patients operated on 
within the selected period, T2 stage was found in 247, 
and T3 stage in 118 patients. In grade groups 2 and 3, 
irrespective of cancer percentages in pathology reports, 
more T3 stage cases were found in grade group 3 when 
compared to grade group 2, which was statistically sig-
nifi cant, p<0.001 (Table 2, Fig. 4). However, grade 
group 2 and grade group 3 patients with ≤10% cancer 
occurrences in fi nal pathology reports after RRP did 
not show any disparity in the occurrence of T3 stage, p 
= 0.96 (Table 3, Fig. 5). Out of the total number of 80 
grade group 2 patients with a percentage of cancer 
≤10%, T2 stage was found in 68 patients (85%) and T3 
stage in 12 patients (15%). Out of the total number of 
59 grade group 3 patients with a percentage of cancer 
≤10%, T2 stage was found in 50 patients (84.7%). T3 
stage was found in 9 patients (15.3%), p = 0.96.
Discussion
Gleason’s assessment was made in 1966 by the pa-
thologist Dr. Donald F Gleason8. Since 1966, the rat-
ing system has undergone several revisions to improve 
t he prognostic value. Th e most signifi cant changes 
Fig. 3. Relationship between grade groups and PSA 
levels: With the increase of grade group PSA increased 
signifi cantly, p<0,001.
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were made in 1997, 2005 and the last, and current one, 
in 20162, 3, 4.
Th e modifi cations of the Gleason grading system 
made by the International Society of Urological Pa-
thology (ISUP) had a signifi cant eff ect on the clinical 
practice of developing prostate cancer, with the Glea-
son score still positioned as a key factor for patient 
management. Th e 2005 ISUP Gleason grading system 
has been greatly appreciated, which is a signifi cant step 
in establishing more repetitive classifi cations of pros-
tate cancer. Th e Gleason score assigned to prostate 
cancer in radical prostatectomy specimens is strongly 
predictive of postoperative progression. Gleason score 
7 tumors are heterogeneous in their biologic behavior. 
Th e diff erences in the prognoses of tumors with Glea-
son scores 3+4 and 4+3 after radical prostatectomy are 
signifi cant. However, the prognosis of Gleason score 7 
tumors is not uniformly poor. Th e majority of studies 
performed as yet has shown that Gleason score 7 dif-
fers signifi cantly in the progression of the disease or 
unfavorable pathology reports depending on the dom-
inant Gleason.
In the last 15 years, many researches have dealt 
with the question whether the dominant sample in 
Gleason score 7 tumor results (score 3+4 to 4+3) is an 
independent predictor of the progression following 
RRP9, 10, 11, 12,13. Th ey have concluded that Gleason 
scores 3+4 and 4+3 do not have the same  malignant 
potential. Gleason sum 4+3 in the fi nal pathology 
analysis following RRP has a worse prognosis for a 
more signifi cant progression of the disease10. Th is is 
very important, as Gleason score 7 is one of the most 
important factors in the introduction of the new grad-
ing system (grade group system).
However, more research at the beginning of this 
century has shown that the percentage of cancer is a 
very important factor in unfavorable histopathology 
analysis and postoperative progression of the disease14. 
In their research, Freedland et al. have demonstrated 
that the percentage of carcinogenic tissue in biopsy 
specimens after RRP was a better indicator of bio-
chemical relapse and fi nal pathological stage than pre-
operative PSA and GS15. For this reason, cancer per-
centages in pathology reports after RRP must b e taken 
as an essential factor in the occurrence of the T3 stage 
of the disease.
Table 2. Relationship between cancer percentage, grade groups 2 and 3, and T stage on fi nal 
pathology report
T grade Total2 3
Grade group 2 Count 153 31 184
% within grade group 83.2% 16.8% 100.0%
3 Count 67 65 132
% within grade group 50.8% 49.2% 100.0%
Total Count 220 96 316
% within grade group 69.6% 30.4% 100.0%
Fig. 4. Relationship between cancer percentage, grade 
groups 2 and 3, and T stage on fi nal pathology report: 
Irrespective of cancer percentage in pathology reports, 
more T3 stage cases were found in grade group 3 when 
compared to grade group 2, which was statistically 
signifi cant, p<0.001.
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Conclusion
Gleason sum 7 is heterogeneous in its biologic be-
havior. Th e diff erences in prognoses for grade group 2 
and grade 3 patients after RRP are signifi cant, but not 
always. Th e relevance of the percentage of prostate 
cancer after RRP must be considered in the risk as-
sessment process, i.e. lower carcinoma percentage 
(≤10%) in this study.
But what about patients with ≥50% of cancer in the 
fi nal pathology report after RRP? In this study, the to-
Table 3. Relationship between cancer percentage of ≤10%, grade groups 2 and 3, and T stage 
on fi nal pathology report
T grade Total2 3
Grade group 2 Count 68 12 80
% within grade group 85.0% 15.0% 100.0%
3 Count 50 9 59
% within grade group 84.7% 15.3% 100.0%
Total Count 118 21 139
% within grade group 84.9% 15.1% 100.0%
Fig. 5. Relationship between cancer percentage of ≤10%, 
grade groups 2 and 3 and T stage on the fi nal pathology 
report: Patients with both grade group 2 and 3 and with 
the percentage of ≤10% cancer in the fi nal pathology 
report after RRP did not show any diff erence in the 
occurrence of T3 stage, p = 0,96.
tal of 20 patients with the percentage of cancer ≥50% 
and only 8 patients in grade groups 2 and 3 were re-
ported, which is insuffi  cient for any further investiga-
tion.
Seeing that this is only a part of the study con-
ducted in the period between 1 January 2005 and 31 
December 2016, and covering the total of 1.800 pa-
tients who had undergone surgery, a suffi  cient number 
of patients with a high percentage of cancer are ex-
pected to answer the above question.
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Sažetak
PATOHISTOLOŠKI NALAZ NAKON RADIKALNE PROSTATEKTOMIJE 
TEMELJENE NA NOVOM SUSTAVU OCJENJIVANJA
B. Spajić, S. Nikles, I. Grubišić, M. Knežević, S. Shoipi, M. Ulamec, G. Štimac, I. Tomašković i B. Ružić
Kao jedan od glavnih uzroka uvođenja novih gradus skupina bio je Gleasonov zbroj 7, koji se bitno razlikovao u progno-
zi bolesti ovisno o primarnom Gleasonu. U ovom istraživanju usporedili smo gradus skupinu 2 (GZ 3+4) i gradus skupinu 3 
(GZ 4+3) u pojavnosti T3 stadija kod pacijenata s ≤10% karcinoma u patohistološkom nalazu nakon retropubične radikalne 
prostatektomije, klinički lokaliziranog karcinoma prostate. Studijom je obuhvaćeno 365 pacijenata s klinički lokaliziranim 
karcinomom prostate koji su podvrgnuti radikanoj retropubičnoj prostatektomiji između 1. siječnja 2015. i 31. prosinca 2016. 
godine. Najzastupljenije gradus skupine bile su gradus skupina 2 s 50,41% i gradus skupina 3, s udjelom od 36,16%. Postotak 
karcinoma u PHD nalazu nakon RRP bio je u rasponu od 5 do 80%, prosjek 20,1%. Kod gradus skupina 2 i 3, neovisno o 
postotku karcinoma prostate u konačnom PHD nalazu, bilo je statistički značajno više T3 stadija u gradus skupini 3 u od nosu 
na gradus skupinu 2, p=0,001. Međutim, pacijenti gradus skupina 2 i 3 s postotkom karcinoma ≤10% u konačnom PHD 
nalazu nakon RRP nisu pokazali razliku u pojavnosti T3 stadija, p=0,96. Razlike u prognozi za pacijente gradus skupine 2 i 
gradus skupine 3 nakon RRP su značajne, ali ne uvijek. Svakako pri procjeni rizika moramo uzeti u obzir i značajnost 
 postotka karcinoma prostate nakon RRP, u ovom istraživanju niži postotak karcinoma (≤10%).
Ključne riječi: Gleason ocjena; Gradus skupine; Karcinom prostate; Patohistološki nalaz; Radikalna prostatektomija
